Who are PEG-interferon alfa-2b's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Besremi, Rosiglitazone and Pegasys/Ribavirin, Reiferon retard, INF1.0 + IBU, Peginterferon alfa-2b Injection, Reiferon Retard in Arm 1.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peg-interferon-alfa-2b.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

PEG-interferon alfa-2b — Competitive Intelligence Brief

PEG-interferon alfa-2b (PEG-interferon alfa-2b) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alfa. Area: Oncology, Immunology, Virology.

marketed Interferon alfa Interferon-alpha receptor (IFNAR) Oncology, Immunology, Virology Biologic Live · refreshed every 30 min

Target snapshot

PEG-interferon alfa-2b (PEG-interferon alfa-2b) — Barbara Ann Karmanos Cancer Institute. PEG-interferon alfa-2b is a pegylated form of interferon alfa-2b that enhances and prolongs immune activation by binding to interferon-alpha receptors on immune cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PEG-interferon alfa-2b TARGET	PEG-interferon alfa-2b	Barbara Ann Karmanos Cancer Institute	marketed	Interferon alfa	Interferon-alpha receptor (IFNAR)
Besremi	ROPEGINTERFERON ALFA-2B	Pharma Essentia Corporation	marketed	Interferon alfa-2b [EPC]	Interferon alpha/beta receptor	2021-01-01
Rosiglitazone and Pegasys/Ribavirin	Rosiglitazone and Pegasys/Ribavirin	Beth Israel Medical Center	marketed	Thiazolidinedione (rosiglitazone) combined with pegylated interferon alfa-2a and nucleoside analog (ribavirin)	PPAR-γ (rosiglitazone); Interferon-α receptor and HCV NS5B polymerase (pegasys/ribavirin)
Reiferon retard	Reiferon retard	MinaPharm Pharmaceuticals	marketed	Interferon alfa-2a (long-acting/sustained-release formulation)	Type I interferon receptor (IFNAR)
INF1.0 + IBU	INF1.0 + IBU	St. Justine's Hospital	marketed	Interferon alfa + NSAID combination	Interferon alfa receptor (IFNAR); COX-1 and COX-2
Peginterferon alfa-2b Injection	Peginterferon alfa-2b Injection	Nanfang Hospital, Southern Medical University	marketed	Interferon alfa	Interferon-alpha receptor (IFNAR)
Reiferon Retard in Arm 1	Reiferon Retard in Arm 1	MinaPharm Pharmaceuticals	marketed	Interferon alfa-2a (long-acting/sustained-release)	Type I interferon receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alfa class)

Barbara Ann Karmanos Cancer Institute · 1 drug in this class
Nanfang Hospital, Southern Medical University · 1 drug in this class
SciClone Pharmaceuticals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PEG-interferon alfa-2b — Competitive Intelligence Brief. https://druglandscape.com/ci/peg-interferon-alfa-2b. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab